@article{fcd219c3727b44d69bf49832e48fde6d,
title = "Relating Pneumococcal Carriage among Children to Disease Rates among Adults before and after the Introduction of Conjugate Vaccines",
abstract = "The use of pneumococcal conjugate vaccines (PCVs) in children has a strong indirect effect on disease rates in adults. When children are vaccinated with PCVs, other serotypes that are not targeted by the vaccine can increase in frequency (serotype replacement) and reduce the direct and indirect benefits of the vaccine. To understand and predict the likely impacts of serotype replacement, it is important to know how patterns in the transmission of serotypes among children relate to disease rates in adults. We used data on pneumococcal carriage and disease from Navajo Nation children and adults collected before and after the routine use of PCVs (1998-2012). Using regression models within a Bayesian framework, we found that serotype-specific carriage and invasiveness (disease incidence divided by carriage prevalence) had similar patterns in children and adults. Moreover, carriage in children, invasiveness in children, and a serotype-specific random intercept (which captured additional variation associated with the serotypes) could predict the incidence serotype-specific pneumococcal disease in adults 18-39 years of age and those 40 years of age or older in the era of routine use of PCVs. These models could help us predict the effects of future pneumococcal vaccine use in children on disease rates in adults, and the modeling approach developed here could be used to test these findings in other settings.",
keywords = "Streptococcus pneumoniae, adults, carriage, colonization, comorbid conditions, conjugate vaccines, pneumococcus",
author = "Weinberger, {Daniel M.} and Grant, {Lindsay R.} and Weatherholtz, {Robert C.} and Warren, {Joshua L.} and O'Brien, {Katherine L.} and Hammitt, {Laura L.}",
note = "Funding Information: D.M.W was supported by grant R56AI110449 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, grant P30AG021342 from the National Institute on Aging, National Institutes of Health (scholar at the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine), grant UL1 TR000142 from the National Institutes of Health (Clinical and Translational Science Award to Yale University), a grant from the Bill and Melinda Gates Foundation, and an investigator-initiated research grant from Pfizer. The collection of the original data used in this analysis was supported by the Native American Research Centers for Health (grant U26IHS300013/03), the Centers for Disease Control and Prevention, the Trasher Research Fund, the National Institute on Minority Health and Health Disparities, National Institutes of Health (grant R01MD004011), and Pfizer (protocol number: 6096A1-4013). L.R.G. and R.W. received research support in the past 3 years from the National Institutes of Health. K.L.O. received pneumococcal research grant funding in the past 3 years from the National Institutes of Health, The Bill and Melinda Gates Foundation, and Gavi, the Vaccine Alliance. Publisher Copyright: {\textcopyright} 2016 The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved.",
year = "2016",
month = jun,
day = "1",
doi = "10.1093/aje/kwv283",
language = "English (US)",
volume = "183",
pages = "1055--1062",
journal = "American journal of epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "11",
}